JP5899773B2 - 更年期障害改善用医薬組成物ならびに飲食物 - Google Patents
更年期障害改善用医薬組成物ならびに飲食物 Download PDFInfo
- Publication number
- JP5899773B2 JP5899773B2 JP2011220787A JP2011220787A JP5899773B2 JP 5899773 B2 JP5899773 B2 JP 5899773B2 JP 2011220787 A JP2011220787 A JP 2011220787A JP 2011220787 A JP2011220787 A JP 2011220787A JP 5899773 B2 JP5899773 B2 JP 5899773B2
- Authority
- JP
- Japan
- Prior art keywords
- lactoferrin
- menopause
- food
- pharmaceutical composition
- drink
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000009245 menopause Effects 0.000 title description 35
- 235000013305 food Nutrition 0.000 title description 29
- 239000008194 pharmaceutical composition Substances 0.000 title description 28
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 94
- 108010063045 Lactoferrin Proteins 0.000 claims description 93
- 102000010445 Lactoferrin Human genes 0.000 claims description 92
- 229940078795 lactoferrin Drugs 0.000 claims description 92
- 235000021242 lactoferrin Nutrition 0.000 claims description 92
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 description 31
- 230000000694 effects Effects 0.000 description 23
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 230000000202 analgesic effect Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- 229960005181 morphine Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002611 ovarian Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- -1 fluidity promoters Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 6
- 238000009505 enteric coating Methods 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000002657 hormone replacement therapy Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000017657 Menopausal disease Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 206010027304 Menopausal symptoms Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000008058 pain sensation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 108010038047 apolactoferrin Proteins 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940072440 bovine lactoferrin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002876 effect on osteoporosis Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003267 reducing disaccharides Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
一般的に、女性は、40代に入ると卵巣機能が低下し始め、50歳前後で閉経を迎える(日本人女性の平均閉経年齢:49.5歳)。卵巣機能の低下に伴い、卵巣から分泌される卵胞ホルモン(エストロゲン)の量が減少すると、***中枢である視床下部や下垂体などが活発に働き、卵巣を刺激する。卵巣がそのような刺激に対しても反応しないと、視床下部は卵巣刺激ホルモンを出す。卵巣刺激ホルモンによってもエストロゲンは十分には分泌されないという現象が生ずると、ホルモン・バランスの乱れが生じ、これが視床下部や下垂体に混乱を生じさせる。混乱が生じた視床下部や下垂体の近傍には、自律神経系が存在するため、そのような混乱の影響により、自律神経系の異常、すなわち不定愁訴が生じる。
身近な人との人間関係の変化なども、不定愁訴をもたらすとされている。例えば、親などの介護の開始、夫の退職による夫との関係の変化、子供の自立や仕事上の立場の変化が、更年期障害発症の契機となる。
本人の性格も、更年期障害の発症やその程度に影響を与える。真面目で、几帳面で完全主義者の人が、更年期障害になりやすいとされている。
牛乳から抽出したラクトフェリン原末(蛋白質として純度95%以上;蛋白質中のラクトフェリンは90%以上)20kgに、乳糖45.6kg、結晶セルロース(商品名:アビセル)16kg、カルボキシメチルセルロース・カルシウム塩1.6kg、ショ糖脂肪酸エステル0.8kgを加え、得られた混合物をミキサーで粉砕し、100メッシュを通過する粉末とした。この混合粉末を打錠機により打錠して、長径8.5mm、重量210mgの錠剤とした。1錠中には、ラクトフェリン原末50mgが含有されている。
コーティング機(フロイント産業(株)製、ハイコーターHCT−48N)に、実施例1で製造した錠剤を入れた。この錠剤に、シェラック9.6質量%、L−アルギニン1.5質量%、ソルビトール1.9質量%、ショ糖脂肪酸エステル2.4質量%、エタノール4.8質量%、精製水79.8%よりなる腸溶性コーティング液を噴霧し、対錠剤比で8〜9質量%の腸溶性コーティングを施して製品とした。
コーティング機(フロイント産業(株)製、ハイコーターHCT−48N)に、実施例1で製造した錠剤を入れた。この錠剤に、カルボキシメチルセルロース9質量%、グリセリン脂肪酸エステル1質量%、エタノール45質量%、塩化メチレン45質量%よりなる腸溶性コーティング液を噴霧し、対錠剤比で12質量%の腸溶性コーティングを施して製品とした。
コーティング機(フロイント産業(株)製、ハイコーターHCT−48N)に、実施例1で製造した錠剤を入れた。この錠剤に、トウモロコシ穀粒から得られる蛋白質であるゼイン8質量部、グリセリン2質量部を、70質量%エタノール水溶液150質量部に溶解してなる腸溶性コーティング液を噴霧し、対錠剤比で10質量%のコーティングが施されてなる錠剤を得た。
コーティング機(フロイント産業(株)製、ハイコーターHCT−48N)に、実施例1で製造した錠剤を入れた。この錠剤に、セラック30質量部、ヒマシ油7質量部をイソプロパノール63質量部に溶解してなる腸溶性コーティング液を噴霧し、対錠剤比で10質量%のコーティングが施されてなる錠剤を得た。
実施例1で製造した錠を用いて実施例2で製造した腸溶性ラクトフェリン錠を、ボランティアの被験者に経口摂取させ、更年期障害の自覚症状が改善するか否かを試験した。
本試験のプロトコールは、次のとおりであった。
(1)被験者は、試験開始前の更年期障害の自覚症状について、その程度(更年期スコア;日本女性医学会が制定)を記入した。
(2)被験者は、試験開始に先立ち、ラクトフェリンについて説明を受けた。先ず、ラクトフェリンが生体内で産生・分泌されること及びその機能の説明を受け、更年期障害の際にも現れるドライアイ(角膜乾燥症)、ドライマウス(口腔乾燥症)に対して効果があるとの説明を受けた。また、動物実験において、鎮痛効果が既に証明されているとの説明を受けた。この試験は、更年期障害に対して効果が得られるか否かを調査するためのものであり、現在行っている治療は継続してもよい旨の説明を受けた。
(3)被験者は、試験開始から3ヶ月間、与えられた腸溶性ラクトフェリン錠(1錠中にラクトフェリンを50mg含有)3錠を毎日摂取した(非盲検試験)。被験者は、朝、昼、晩の食前あるいは食後に各1錠を服用するか、又は、1日に一度、3錠を服用した。
(4)被験者は、試験終了直後に、更年期障害の自覚症状について、その程度(更年期スコア)を記入した。
被験者が更年期スコアを記入した症状は、熱感に関するもの(1.顔がほてる、2.上半身がほてる、3.のぼせる、4.汗をかきやすい)、不眠に関するもの(5.夜なかなか寝付けない、6.夜眠っていても目をさましやすい)、神経質・憂鬱感に関するもの(7.興奮しやすく、イライラすることが多い、8.いつも不安感がある、9.神経質である、10.くよくよし、憂鬱になることが多い)、倦怠感に関するもの(11.疲れやすい、12.目が疲れる)、記憶障害に関するもの(13.物事が覚えにくくなったり、物忘れが多い)、胸部症状に関するもの(14.胸がどきどきする、15.胸がしめつけられる)、疼痛症状に関するもの(16.頭が重かったり、度々頭痛に見まわれる、17.肩や首がこる、18.背中や腰が痛む、19.手足の節々(関節)に痛みがある)、知覚異常に関するもの(20.腰や手足が冷える、21.手足(指)がしびれる、22.音に敏感となっている)である。被験者は、ビジュアル・アナログ・スケール(VAS)に、各症状についてその強度(無乃至強)の位置に印を付けた。印の位置を、症状が無い場合を0とし且つ強い場合を10として、数値化した。
データの解析は、統計ソフトJAMP8を用い、一元配置検定(カイ2乗近似)で処理した。平均値と標準誤差とを求めた。
被験者は、48歳乃至53歳の女性8名(平均値±標準偏差;50.25±2.05)であった。本試験開始前、全員がホルモン補充療法又は漢方薬治療を行っていた。結果を表1及び図1乃至8に示す。表1及び図1乃至8には、平均値±標準誤差の値を示した。なお、図1乃至8において、黒棒は試験開始前(「0か月」と表示)を、白棒は試験終了直後(「3か月」と表示)のデータを示す。
Claims (2)
- ラクトフェリンを有効成分として含有することを特徴とする更年期障害改善用腸溶性製剤。
- ラクトフェリンの1日あたりの投与量が10mg乃至15,000mgである、請求項1記載の腸溶性製剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011220787A JP5899773B2 (ja) | 2011-10-05 | 2011-10-05 | 更年期障害改善用医薬組成物ならびに飲食物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011220787A JP5899773B2 (ja) | 2011-10-05 | 2011-10-05 | 更年期障害改善用医薬組成物ならびに飲食物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016017614A Division JP6082941B2 (ja) | 2016-02-02 | 2016-02-02 | 更年期障害改善用医薬組成物ならびに飲食物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013079218A JP2013079218A (ja) | 2013-05-02 |
JP2013079218A5 JP2013079218A5 (ja) | 2014-11-06 |
JP5899773B2 true JP5899773B2 (ja) | 2016-04-06 |
Family
ID=48525918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011220787A Active JP5899773B2 (ja) | 2011-10-05 | 2011-10-05 | 更年期障害改善用医薬組成物ならびに飲食物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5899773B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018043964A (ja) * | 2016-09-16 | 2018-03-22 | サンスター株式会社 | 睡眠改善用組成物 |
JP2019011302A (ja) * | 2017-06-30 | 2019-01-24 | サンスター株式会社 | 生体リズム改善用組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4647940B2 (ja) * | 2004-06-07 | 2011-03-09 | 花王株式会社 | アロマターゼ活性化剤 |
CA2600460A1 (en) * | 2005-03-08 | 2006-09-14 | Fonterra Co-Operative Group Limited | High pressure processing of metal ion lactoferrin |
JP5033115B2 (ja) * | 2008-12-15 | 2012-09-26 | 株式会社Nrlファーマ | ドライアイを治療又は予防する新規医薬組成物並びに加工食品 |
-
2011
- 2011-10-05 JP JP2011220787A patent/JP5899773B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013079218A (ja) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6285049B2 (ja) | 性ホルモンのバランスの乱れに起因する症状の予防又は改善剤 | |
JP2008247883A (ja) | 月経不順改善用組成物 | |
US11116781B2 (en) | Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome | |
JP2006182679A (ja) | ストレス性胃炎予防・治療剤 | |
JP5899773B2 (ja) | 更年期障害改善用医薬組成物ならびに飲食物 | |
US10835564B2 (en) | Composition for preventing and treating premature ovarian failure, containing Evodia rutaecarpa bentham extract having protective activity against ovotoxicity | |
WO2016112552A1 (zh) | 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 | |
JP6082941B2 (ja) | 更年期障害改善用医薬組成物ならびに飲食物 | |
JP5106809B2 (ja) | ラクトフェリンを含有する医薬組成物ならびに加工食品 | |
JP7257399B2 (ja) | 多嚢胞性卵巣症候群に罹患している女性患者における胚着床率を高める方法 | |
KR20180102403A (ko) | 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 | |
JP2005075763A (ja) | 動物用薬剤 | |
Swaab et al. | Functional teratogenic effects of chemicals on the developing brain. Monographs in Neuronal Sciences | |
JP2007230954A (ja) | 睡眠誘導剤及びストレス性不眠症改善剤 | |
TW201834680A (zh) | 性早熟症的預防或改善用食品組合物及性早熟症的預防或治療用藥學組合物 | |
Swaab et al. | Functional teratogenic effects of chemicals on the developing brain | |
JP5022454B2 (ja) | 卵巣機能改善剤 | |
RU2790696C2 (ru) | Способ повышения частоты имплантации эмбриона у субъекта женского пола, страдающего синдромом поликистозных яичников | |
JP2019034924A (ja) | 妊娠中の母子の健康状態改善剤 | |
EP1941874A1 (en) | Colonic delivery-type therapeutic agent for inflammatory bowel disease | |
Dom-SERTRALINE | DOMINION PHARMACAL | |
Swaab et al. | Mechanisms underlying the behavioral teratogenic effects of chemicals on the developing brain | |
JP2022533667A (ja) | 骨損失疾患の予防、改善または治療のためのchp(シクロ-ヒスプロ)および副甲状腺ホルモンを含む組成物の用途 | |
KR20190037222A (ko) | 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 | |
TWI307627B (en) | Drospirenone for hormone replacement therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140916 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150918 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5899773 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |